BPC’s Health Innovation Initiative hosted a discussion to explore priorities for medical innovation in the lame duck and the new administration.
Congress is currently considering legislation to accelerate the delivery of life-saving, safe, and effective cures for patients, including important administration priorities associated with precision medicine and cancer. The Trump transition team is also now hard at work identifying new leadership and preparing for the new administration. Finally, the new Congress is expected to begin work on must-pass prescription drug and medical device user fee reauthorization bills early in 2017.
Emerging therapies offer the promise of cures for those with Alzheimer’s, cancer, Parkinson’s, and other life-threatening diseases, yet on average, it takes $2 billion and a decade for new drugs and other therapies to get to market.
Read the Brief | Realizing the Promise of Medical Innovation
Panel discussion with:
Francis S. Collins, MD, PhD
Director, National Institutes of Health
President and CEO, Biotechnology Industry Organization
Andrew von Eschenbach, MD
President, Samaritan Health Initiative
Former Commissioner, Food and Drug Administration
Ellen V. Sigal, PhD
Founder and Chair, Friends of Cancer Research
Director of Health Innovation, BPC